Company intelligence / Profile preview

rEVO Biologics

Framingham, Massachusetts, United Statesorpha.net ↗

Ownership: Private
Employees: ~137
Development stage: Commercial

Overview

The company's lead product ATryn (Antithrombin Recombinant) is approved for use in patients with hereditary antithrombin deficiency. They were exploring additional applications for ATryn including early onset preeclampsia through a Phase 3 clinical trial called PRESERVE-1.

Therapeutic areas: Women's HealthHematologyCardiovascularOphthalmology
Modalities: Recombinant proteinsTherapeutic proteinsMonoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

antithrombin alfa

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on rEVO Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rEVO Biologics.

Explore the full profile